Loading...
Market
Region with highest increase in Rybelsus sales by end of 2025?
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
Novo Nordisk annual financial reports
Story
Novo Nordisk's Rybelsus Cuts Cardiovascular Risk by 14% in SOUL Trial
Oct 21, 2024, 10:15 AM
Novo Nordisk's oral semaglutide, marketed as Rybelsus, has demonstrated a 14% reduction in the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes, according to the results of the SOUL trial. The late-stage study, announced on Monday, involved over 9,600 patients with type 2 diabetes and heart or kidney disease. Novo Nordisk plans to file for regulatory approval of a label expansion for Rybelsus in both the US and EU around the turn of the year. The drug, a tablet version of Ozempic, showed significant potential in reducing the risk of heart attacks and strokes, which may drive broader use of the medication.
View original story
Similar markets
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Africa • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%